-
公开(公告)号:US09187522B2
公开(公告)日:2015-11-17
申请号:US14296907
申请日:2014-06-05
申请人: Receptos, Inc.
发明人: Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号: A61K31/33 , C07K5/072 , C07D233/54 , C07D233/60 , C07D401/04 , C07D403/04 , C07D239/26 , C07D239/34 , C07D409/12 , C07D413/04 , C07D241/08 , C07D417/12 , C07D255/02 , C07D263/32 , C07D271/06 , C07D271/107 , C07D495/04 , C07D277/24 , C07D285/12 , C07D211/22 , A61K31/4245 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/505 , A61K31/506 , A61K31/551 , A61K38/26 , C07D243/08 , C07D403/12 , C07D413/10 , C07D413/12 , C07D413/14 , A61K45/06 , C07D291/00 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K38/05 , C07D277/30 , C07D285/08
CPC分类号: C07K5/06113 , A61K31/33 , A61K31/4245 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/505 , A61K31/506 , A61K31/551 , A61K38/05 , A61K38/26 , A61K45/06 , C07D211/22 , C07D233/54 , C07D233/60 , C07D239/26 , C07D239/34 , C07D241/08 , C07D243/08 , C07D255/02 , C07D263/32 , C07D271/06 , C07D271/107 , C07D277/24 , C07D277/30 , C07D285/08 , C07D285/12 , C07D291/00 , C07D401/04 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D495/04
摘要: The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
摘要翻译: 本发明涉及调节胰高血糖素样肽1(GLP-1)受体的化合物,其合成方法及其治疗和/或预防用途的方法。 这些化合物独立地用作GLP-1受体的调节剂或增强剂,或者作为受体配体包括GLP-1肽GLP-1(7-36)和GLP-1(9-36)或与基于肽的疗法 ,其中A,B,C,Y 1,Y 2,Z,R 1,R 2,R 3,R 3,R 3,R 3, R4,R5,W1,n,p和q如本文所定义。
-
公开(公告)号:US20150038416A1
公开(公告)日:2015-02-05
申请号:US14296907
申请日:2014-06-05
申请人: Receptos, Inc.
发明人: Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号: C07K5/072 , A61K45/06 , A61K31/4245 , C07D413/14 , A61K31/4545 , C07D413/04 , A61K31/4439 , A61K31/4709 , A61K38/05 , C07D277/30 , A61K31/426 , C07D285/08 , A61K31/433 , C07D239/26 , A61K31/505 , C07D271/06
CPC分类号: C07K5/06113 , A61K31/33 , A61K31/4245 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/505 , A61K31/506 , A61K31/551 , A61K38/05 , A61K38/26 , A61K45/06 , C07D211/22 , C07D233/54 , C07D233/60 , C07D239/26 , C07D239/34 , C07D241/08 , C07D243/08 , C07D255/02 , C07D263/32 , C07D271/06 , C07D271/107 , C07D277/24 , C07D277/30 , C07D285/08 , C07D285/12 , C07D291/00 , C07D401/04 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D495/04
摘要: The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
摘要翻译: 本发明涉及调节胰高血糖素样肽1(GLP-1)受体的化合物,其合成方法及其治疗和/或预防用途的方法。 这些化合物独立地用作GLP-1受体的调节剂或增强剂,或者作为受体配体包括GLP-1肽GLP-1(7-36)和GLP-1(9-36)或与基于肽的疗法 ,其中A,B,C,Y 1,Y 2,Z,R 1,R 2,R 3,R 3,R 3,R 3, R4,R5,W1,n,p和q如本文所定义。
-
公开(公告)号:US20130178420A1
公开(公告)日:2013-07-11
申请号:US13712624
申请日:2012-12-12
申请人: RECEPTOS, INC.
发明人: Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号: C07D413/14 , A61K31/4245 , C07D413/10 , A61K31/454 , A61K31/4545 , A61K31/4709 , C07D239/26 , A61K31/505 , C07D413/12 , A61K31/506 , C07D403/12 , C07D403/04 , C07D243/08 , A61K31/551 , A61K38/26 , C07D271/06
CPC分类号: C07K5/06113 , A61K31/33 , A61K31/4245 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/505 , A61K31/506 , A61K31/551 , A61K38/05 , A61K38/26 , A61K45/06 , C07D211/22 , C07D233/54 , C07D233/60 , C07D239/26 , C07D239/34 , C07D241/08 , C07D243/08 , C07D255/02 , C07D263/32 , C07D271/06 , C07D271/107 , C07D277/24 , C07D277/30 , C07D285/08 , C07D285/12 , C07D291/00 , C07D401/04 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D495/04
摘要: The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
摘要翻译: 本发明涉及调节胰高血糖素样肽1(GLP-1)受体的化合物,其合成方法及其治疗和/或预防用途的方法。 这些化合物独立地用作GLP-1受体的调节剂或增强剂,或者作为受体配体包括GLP-1肽GLP-1(7-36)和GLP-1(9-36)或与基于肽的疗法 ,其中A,B,C,Y 1,Y 2,Z,R 1,R 2,R 3,R 3,R 3,R 3, R4,R5,W1,n,p和q如本文所定义。
-
公开(公告)号:US08778923B2
公开(公告)日:2014-07-15
申请号:US13712624
申请日:2012-12-12
申请人: Receptos, Inc.
发明人: Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号: A61K31/33 , C07D291/00
CPC分类号: C07K5/06113 , A61K31/33 , A61K31/4245 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/505 , A61K31/506 , A61K31/551 , A61K38/05 , A61K38/26 , A61K45/06 , C07D211/22 , C07D233/54 , C07D233/60 , C07D239/26 , C07D239/34 , C07D241/08 , C07D243/08 , C07D255/02 , C07D263/32 , C07D271/06 , C07D271/107 , C07D277/24 , C07D277/30 , C07D285/08 , C07D285/12 , C07D291/00 , C07D401/04 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D495/04
摘要: The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
摘要翻译: 本发明涉及调节胰高血糖素样肽1(GLP-1)受体的化合物,其合成方法及其治疗和/或预防用途的方法。 这些化合物独立地用作GLP-1受体的调节剂或增强剂,或者作为受体配体包括GLP-1肽GLP-1(7-36)和GLP-1(9-36)或与基于肽的疗法 ,其中A,B,C,Y 1,Y 2,Z,R 1,R 2,R 3,R 3,R 3,R 3, R4,R5,W1,n,p和q如本文所定义。
-
公开(公告)号:US3888877A
公开(公告)日:1975-06-10
申请号:US34468273
申请日:1973-03-26
申请人: SCHERING CORP
发明人: LEHN JEAN-MARIE
IPC分类号: C07C51/27 , C07C59/125 , C07C59/305 , C07C59/68 , C07C323/25 , C07D209/48 , C07D273/00 , C07D291/00 , C07D498/08 , C07D513/08 , C07D515/08 , C07F9/50 , C07F9/54 , C07F9/6571 , C07D93/00
CPC分类号: C07D209/48 , C07C51/27 , C07C59/125 , C07C59/305 , C07C59/68 , C07C323/25 , C07D273/00 , C07D291/00 , C07D513/08 , C07D515/08 , C07F9/5004 , C07F9/5449 , C07F9/657163
摘要: Novel macrocyclic (monocyclic and bicyclic) compounds having nitrogen bridgehead atoms and having in the hydrocarbon bridging chains at least two additional hetero atoms selected from the group consisting of sulfur, oxygen, and nitrogen, when admixed with a compatible cation-donor compound form stable cationcontaining macrocyclic complexes which, in turn, can be conveniently dissociated by addition of acid or a quaternizing agent. The novel macrocyclics are valuable for use in the same way and for the same purposes as chelating agents. The macrocyclic compounds are prepared by condensation reactions carried out via high dilution techniques, e.g. by condensing a substituted hydrocarbon di-carbonyl halide with a substituted hydrocarbon having terminal primary or secondary amino groups followed by reduction of the resulting lactam or, alternatively, by condensing a substituted hydrocarbon having terminal secondary or tertiary amino groups which have at least one hydrogenolyzable group with a substituted hydrocarbon di-halide (or di-sulfonate) followed by hydrogenolyzation of the macrocyclic compound thereby formed.
-
公开(公告)号:US06350545B2
公开(公告)日:2002-02-26
申请号:US09139374
申请日:1998-08-25
IPC分类号: H01M1040
CPC分类号: C08F30/04 , C07C307/02 , C07C311/48 , C07D285/00 , C07D291/00 , C07D291/08 , C07F17/00 , H01M6/181 , H01M10/052 , H01M10/0568
摘要: Novel sulfonylinide and sulfonylmethide compounds are described which are useful as conductive salts. Also described is the use of the above compounds in salt form in battery electrolytes, particular salts having mixed perfluorocaron and hydrocarbon groups or having all hydrocarbon groups. The above salts are less expensive to produce and still exhibit excellent conductivity and low corrosivity.
摘要翻译: 描述了可用作导电盐的新型磺酰亚胺和磺酰基甲基化合物。 还描述了在电池电解质中使用上述盐形式的化合物,具有混合的全氟化碳和烃基或具有全部烃基的特定盐。 上述盐生产成本较低,仍然表现出优异的导电性和低腐蚀性。
-
公开(公告)号:US20010008736A1
公开(公告)日:2001-07-19
申请号:US09139374
申请日:1998-08-25
IPC分类号: H01M006/18 , H01M006/16 , H01M010/40 , C07C313/00 , C07D341/00 , C07D409/00 , C07D495/00 , C07C315/00 , C07D307/50 , C07D307/93
CPC分类号: C08F30/04 , C07C307/02 , C07C311/48 , C07D285/00 , C07D291/00 , C07D291/08 , C07F17/00 , H01M6/181 , H01M10/052 , H01M10/0568
摘要: Novel sulfonylimide and sulfonylmethide compounds are described which are useful as conductive salts. Also described is the use of the above compounds in salt form in battery electrolytes, particular salts having mixed perfluorocarbon and hydrocarbon groups or having all hydrocarbon groups. The above salts are less expensive to produce and still exhibit excellent conductivity and low corrosivity.
摘要翻译: 描述了可用作导电盐的新型磺酰亚胺和磺酰基甲基化合物。 还描述了在电池电解质中使用上述盐形式的化合物,特别是具有混合的全氟化碳和烃基或具有全部烃基的盐。 上述盐生产成本较低,仍然表现出优异的导电性和低腐蚀性。
-
-
-
-
-
-